Evidence map›Paper›PMID 22252804›Full record

Trial reportAntimicrobial agents and chemotherapy2012

Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.

Khin Maung Lwin, Aung Pyae Phyo, Joel Tarning, Warunee Hanpithakpong, Elizabeth A Ashley, Sue J Lee, Phaikyeong Cheah, Pratap Singhasivanon, Nicholas J White, Niklas Lindegårdh and 1 more

2 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 55 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 6 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02315690 phase3completednot on this mapstarted 2015, after this paper: background citation

Evaluating the Effectiveness and Feasibility of Reactive Focal Mass Drug Administration vs. Reactive Case Detection as a Community Level Intervention in Response to a Passively Identified Index Malaria Case in Swaziland

TypeinterventionalSponsorUniversity of California, San FranciscoRan2015 to 2017Enrolled4,000ConditionsMalariaArmsdihydroartemisinin-piperaquine (DHAp), reactive case detection
NCT04844099 phase3completednot on this mapstarted 2021, after this paper: background citation

Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)

TypeinterventionalSponsorLiverpool School of Tropical MedicineRan2021 to 2023Enrolled723ConditionsSickle Cell Anemia in Children, MalariaArmsDihydroartemisinin Piperaquine
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 6 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Khin Maung LwinShoklo Malaria Research Unit, Mae Sod, Thailand.
Aung Pyae Phyo
Joel Tarning
Warunee Hanpithakpong
Elizabeth A Ashley
Sue J Lee
Phaikyeong Cheah
Pratap Singhasivanon
Nicholas J White
Niklas Lindegårdh
François Nosten
Mahidol University · THUniversity of Oxford · GBMahidol Oxford Tropical Medicine Research Unit · THShoklo Malaria Research Unit · THChurchill Hospital · GB

Funding

Wellcome Trust 089275Wellcome Trust 093956
6 · The paper itself

Abstract

Intermittent preventive treatment (IPT) is increasingly used to reduce malaria morbidity and mortality in children and pregnant women. The efficacy of IPT depends on the pharmacokinetic and pharmacodynamic properties of the antimalarial drugs used. Healthy adult male volunteers whose occupation put them at high risk of malaria on the Northwest border of Thailand were randomized to receive a 3-day-treatment dose of dihydroartemisinin-piperaquine monthly (DPm) or every 2 months (DPalt) or an identical placebo with or without fat (6.4 g/dose) over a 9-month period. All volunteers were monitored weekly. One thousand adults were recruited. Dihydroartemisinin-piperaquine was well tolerated. There were 114 episodes of malaria (49 Plasmodium falciparum, 63 P. vivax, and 2 P. ovale). The protective efficacy against all malaria at 36 weeks was 98% (95% confidence interval [CI], 96% to 99%) in the DPm group and 86% (95% CI, 81% to 90%) in the DPalt group (for both, P < 0.0001 compared to the placebo group). As a result, the placebo group also had lower hematocrits during the study (P < 0.0001). Trough plasma piperaquine concentrations were the main determinant of efficacy; no malaria occurred in participants with a trough concentration above 31 ng/ml. Neither plasma piperaquine concentration nor efficacy was influenced by the coadministration of fat. DPm is safe to use and is effective in the prevention of malaria in adult males living in an area where P. vivax and multidrug-resistant P. falciparum malaria are endemic.

Indexed as

AdolescentAdultAgedAntimalarialsArtemisininsChemopreventionDietary FatsDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationHematocritHumansMalaria, FalciparumMalaria, VivaxMaleMiddle AgedAntimalarialsArtemisininsartenimolDietary FatspiperaquinePiperazinesPlacebosQuinolines

Identifiers

PMID22252804
PMCPMC3294930
OpenAlexW2070197127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.